You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 10, 2024

OXAYDO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Oxaydo, and what generic alternatives are available?

Oxaydo is a drug marketed by Zyla and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in six countries.

The generic ingredient in OXAYDO is oxycodone hydrochloride. There are nineteen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Oxaydo

A generic version of OXAYDO was approved as oxycodone hydrochloride by SPECGX LLC on June 30th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OXAYDO?
  • What are the global sales for OXAYDO?
  • What is Average Wholesale Price for OXAYDO?
Summary for OXAYDO
International Patents:13
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 8
Clinical Trials: 1
Drug Prices: Drug price information for OXAYDO
What excipients (inactive ingredients) are in OXAYDO?OXAYDO excipients list
DailyMed Link:OXAYDO at DailyMed
Drug patent expirations by year for OXAYDO
Drug Prices for OXAYDO

See drug prices for OXAYDO

Recent Clinical Trials for OXAYDO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Stanford UniversityPhase 3

See all OXAYDO clinical trials

Pharmacology for OXAYDO
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Paragraph IV (Patent) Challenges for OXAYDO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OXAYDO Tablets oxycodone hydrochloride 5 mg and 7.5 mg 202080 1 2012-02-07

US Patents and Regulatory Information for OXAYDO

OXAYDO is protected by two US patents.

Patents protecting OXAYDO

Methods and compositions for deterring abuse of opioid containing dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Abuse deterrent compositions and methods of making same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OXAYDO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 ⤷  Sign Up ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 ⤷  Sign Up ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 ⤷  Sign Up ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 ⤷  Sign Up ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 ⤷  Sign Up ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 ⤷  Sign Up ⤷  Sign Up
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for OXAYDO

See the table below for patents covering OXAYDO around the world.

Country Patent Number Title Estimated Expiration
Australia 2010200979 Methods and compositions for deterring abuse of opioid containing dosage forms ⤷  Sign Up
European Patent Office 1694260 PROCEDES ET COMPOSITIONS POUR EMPECHER UN ABUS DE FORMES PHARMACEUTIQUES CONTENANT DES OPIOIDES (METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF OPIOID CONTAINING DOSAGE FORMS) ⤷  Sign Up
Spain 2637338 ⤷  Sign Up
Israel 175863 PHARMACEUTICAL COMPOSITIONS FOR DETERRING ABUSE OF OPIOID CONTAINING DOSAGE FORMS ⤷  Sign Up
European Patent Office 2420225 Procédés et compositions permettant d'empêcher l'abus d'opioïde contenant des formes de dosage (Methods and compositions for deterring abuse of opioid containing dosage forms) ⤷  Sign Up
Australia 2017239544 Methods and compositions for deterring abuse of opioid containing dosage forms ⤷  Sign Up
Australia 2015264950 Methods and compositions for deterring abuse of opioid containing dosage forms ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OXAYDO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 92292 Luxembourg ⤷  Sign Up PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.